Metastatic Non‐Myofibroblastic Sarcoma Harbouring EML4‐ALK Fusion—Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations
ABSTRACT Background Anaplastic lymphoma kinase (ALK) rearrangements are rare in non‐myofibroblastic sarcoma and there is limited data on the efficacy of ALK tyrosine kinase inhibitors (TKIs) and mechanisms of resistance in these patients. Case A 58 year‐old man with metastatic non‐myofibroblastic sa...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-08-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.2164 |